Your browser doesn't support javascript.
loading
Five-year morbidity and mortality rates in a U.S. population with obesity with and without prediabetes.
Ford, Janet H; Lage, Maureen J; Boye, Kristina S; Bae, Jay P; Terrell, Kendra A; Bunck, Mathijs C.
  • Ford JH; Value, Evidence and Outcomes, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 36255, United States of America. Electronic address: ford_janet@lilly.com.
  • Lage MJ; HealthMetrics Outcomes Research, 17 Benton's Knoll, Guilford, CT 06437, United States of America. Electronic address: lagemj@hlthmetrics.com.
  • Boye KS; Value, Evidence and Outcomes, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 36255, United States of America. Electronic address: boyd_kristina_secnik@lilly.com.
  • Bae JP; Value, Evidence and Outcomes, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46226, United States of America. Electronic address: bae_jay@lilly.com.
  • Terrell KA; Value, Evidence and Outcomes, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46226, United States of America. Electronic address: kendra_terrell@lilly.com.
  • Bunck MC; Medical Development, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46226, United States of America. Electronic address: bunck_mathijs@lilly.com.
J Diabetes Complications ; 37(5): 108454, 2023 05.
Article en En | MEDLINE | ID: mdl-37004499
ABSTRACT

AIMS:

This research examines the prevalence of morbidity and mortality among people with obesity with or without prediabetes.

METHODS:

This observational study uses Optum® Market Clarity deidentified data from 2007 to 2020. Individuals with obesity without prediabetes (obesity only) were matched 11 to adults with prediabetes plus obesity based upon age, sex, race, ethnicity, and region. Age and sex adjusted prevalence rates and 95 % CIs were calculated for morbidity and mortality for each 365-day period post index date and over the entire 5-year post-period.

RESULTS:

After 5-years, the adjusted mortality rate was 10.1 % for adults with obesity plus prediabetes and 6.9 % for adults with obesity only (p < 0.05). Five years post index date, the prevalence of type 2 diabetes was 25.3 % for people with obesity plus prediabetes and 9.2 % for people with obesity only (p < 0.05). Prevalence rates after 5 years for atherosclerotic cardiovascular disease (13.1 % v 8.1 %), composite cardiovascular outcome (7.0 % v 4.4 %) and composite cardio-renal outcome (8.9 % v 5.0 %) were significantly higher for adults with obesity plus prediabetes compared to adults with obesity only (all p < 0.05).

CONCLUSIONS:

Results of this study indicate that the presence of prediabetes contributes to the development of additional morbidity and mortality in adults with obesity.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estado Prediabético / Diabetes Mellitus Tipo 2 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estado Prediabético / Diabetes Mellitus Tipo 2 Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article